期刊文献+

甲磺酸加替沙星氯化钠注射液与乳酸环丙沙星注射液治疗急性细菌性感染随机对照临床研究

下载PDF
导出
摘要 目的评价甲磺酸加替沙星氯化钠注射液治疗急性细菌性感染的有效性和安全性。方法采用区组分层均衡随机单盲试验设计,分别完成甲磺酸加替沙星氯化钠注射液试验药(n=20)及对照药(乳酸环丙沙星,n=23)的临床试验。结果甲磺酸加替沙星氯化钠注射液与乳酸环丙沙星注射液的临床有效率分别为100%和91.30%,细菌学有效率分别为100%和89.47%,细菌清除率均为100%,不良反应发生率分别为13.04%、4.35%。结论甲磺酸加替沙星氯化钠注射液是一种安全有效的广谱抗菌药物,抗菌活性强,可用于治疗多种细菌引起的感染。
出处 《四川大学学报(医学版)》 CAS CSCD 北大核心 2005年第4期596-598,共3页 Journal of Sichuan University(Medical Sciences)
  • 相关文献

参考文献7

  • 1Wakabayshi E,Mitsuhashi S.In vitro antibacterial activity of AM-1155,novel 6-fluoro-8-methoxy quinolone.Antimicrob Agents Chemother,1994;38(3):594.
  • 2李家泰,刘健,王彤,朱琪,刘燕.盐酸加替沙星(Gatifloxacin)体外抗菌作用[J].中国临床药理学杂志,2001,17(6):403-409. 被引量:40
  • 3张能江,张淑华,庄镇华.加替沙星对金黄色葡萄球菌的体外抗菌活性[J].中国抗生素杂志,2002,27(12):753-755. 被引量:6
  • 4Soler N,Lode H,Baldwin R,et al.Radomised Double-Blind Comparision of Oral Gatifloxacin and Co-amoxiclav for Acute Exacerbation of Chronic Bronchitis.Eur J Clin Microbiol Infection Dis,2003;22(3):144.
  • 5Richard GA,Mathew CP,Kirstein JM,et al.Single-dose fluoroquinolone therapy of acute uncomplicated urinary tract infection in women results from a randomized, double -blind, multi-center trial comparing single-dose to 3-day fluoroquinolone regimens.Urology,2002;59(3):334.
  • 6Cox CE, Marbury TC, Pittman WG, et al. A randomized,double-blind,multi-center compaarison of gatifloxacin versus ciprofloxacin in the treatment of complicated urinary tract infection and pyelonephritis.[abstract]Clin Ther,2002;24(2):223.
  • 7Perry CM,Balfour JAB,Lamb HM.Catifoxacin.Drugs,1999;58(4):683.

二级参考文献8

  • 1[1]Hosaka M,Yaxue T, Fukuda H, Tomizawa H, et al.In vitro and in vivo antibacterial activities of AM-1 155, a new 6-fluoro-8-methoxy quinolone. Antimicrobial Agents Chemotherapy, 1992;36:2108~2117.
  • 2[2]Wakabayashi E, Mitsuhashi S. In vitro antibacterial activity of AM-1155, a novel 6-fluoro-8-methyoxy quinolone. Antimicrobial Agents Chemotherapy, 1994;38:594~601.
  • 3[3]Wise R, Brenwald NP, Andrews JM,et al. The activity of the methylpiperazinyl fluoroquinolone CG5501:A comparison with other fluoroquinolones fluoroquinolones. Antimicrobial Chemotherapy, 1997;39:447~452.
  • 4[4]National Committee for Clinical Laboratory Standards. 1998;18.
  • 5[5]Hosaka M,Kinoshita S, Toyama A,et al. Antibacterial Properties of AM-1155, a new 8-methoxy quinolone. Antimicrobial Chemotherapy, 1995; 36:293~301.
  • 6[6]Tanaka M,Takahashi K, Saika T, et al. Development of fluoroquinoloneresistance and mutations involving GyrA and ParC proteins among Neisseria gonorrhoeae in Japan. Urology, 1998; 159:2215~2219.
  • 7[7]Deguchi T, Yasuda M, Nakano M,ea al. Comparison of in vitro antimicrobial activity of AM-1155 with those of tosufloxacin and fleroxacin against clinical isolates of Neisseria gonorrhoeae harboring quinolone resistance alterations in GryA and ParC.Chemotherapy, 1997;43:239~244.
  • 8[8]Nakashima M,Uematsu T,Kosuge K, et al. Single and multiple-dose pharmacolinetics of AM-1155, a new 6-fluoro-8-methoxy quinolone, in humans. Antimicrobial Agents Chemotherapy,1995;39:2635~2640.

共引文献40

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部